

Microvascular Health Solutions Announces Cellular Reconditioning for Kidney Regeneration Using GlycoCheck

CHATTANOOGA, TENNESSEE, USA, August 9, 2022 /EINPresswire.com/ -- Microvascular Health Solutions, LLC (MVHS), a BioRegenx subsidiary based in Alpine, Utah, announces that a new peer-reviewed study has been published using GlycoCheck, a medical testing device exclusively distributed by MVHS. The study, [Ways and Means of Cellular Reconditioning for Kidney Regeneration](#) also included a study of Endocalyx Pro™, an all-natural nutraceutical from MVHS.

The study was published by the American Journal of Nephrology. The authors of the study, S. Ishiko and M.S. Goligorsky, are from the Department of Medicine at New York Medical College. As reported in the study titled, "red blood cells in the microcirculation occupy the central portion of vessels leaving a 'gap' with the surface of the endothelial cells – the width of this area is proportional to the thickness of the endothelial glycocalyx. GlycoCheck is a novel noninvasive technology to evaluate the dimension of the glycocalyx by measuring the 'perfused boundary region (PBR),' which is inversely related to endothelial glycocalyx dimensions. This enables clinicians to analyze in real time endothelial glycocalyx changes in various pathologic conditions, including kidney disease."

"Snoeijs et al. compared the endothelial glycocalyx dimensions in the cortical peritubular



American Journal of Nephrology
In-Depth Topic Review
Editor's Choice - Free Access

Ways and Means of Cellular Reconditioning for Kidney Regeneration

Shoko S. Goligorsky M.D.
S. Ishiko M.D.
Corresponding Author

Keywords: Mitochondrial dysfunction, Systemic dysfunction, Autoimmunity, Glycocalyx loss

doi:10.1093/ajk/kp340
https://doi.org/10.1093/ajk/kp340

ABSTRACT FULLTEXT PDF REFERENCES EXTRA

Abstract

Background: Mitochondrial, systemic, and peritoneal dysfunction, defective autophagy, mitophagy, and proteolysis, as well as the loss of glycocalyx integrity are known contributors to initiation and progression of diverse kidney diseases. These cellular organelles are tightly interactive in health, and during development of a disease, damage in one may propagate to others. By extension, it follows that restoring an individual defect may culminate in a broader restorative spectrum and improvement of cell and organ functions.

Summary: A novel strategy of reconditioning cellular organelle dysfunction, which we define as substitution of pathogenetically gained mass in intracellular elements, damaged in the course of disease and impacting restoration, is hereby outlined in this overview. Individual therapeutic reconditioning approaches targeting selected organelles are cataloged. We anticipate that the proposed reconditioning strategy in the future may avoid the arrival of regenerative medicine and nephrology. **Key Message:** The arrival of regenerative medicine and nephrology, consisting of organ transplantation, use of stem cells, cell-based approaches, cell reconditioning strategies, and organ engineering has been anticipated by the reconditioning strategy. The latter is based on the reconditioning of the built-in and replacement of diverse cellular organelles contributes to pathogenesis of kidney disease and (2) individual organelles are functionally interrelated, which explains the "domino effect" leading to their dysfunction. Reconditioning these advantage of these facts and, while initially directed to restore the function of individual cellular organelles, culminates in the propagation of a therapeutic intervention to account for improved cell and organ function. Examples of such interventions are briefly summarized along the presentation of selective cellular organelles contributing to pathogenesis of kidney disease.

© 2022 S. Karger AG, Basel

Cellular Reconditioning for Kidney Regeneration Using GlycoCheck




BioRegenx



GlycoCheck Training: Get Started

Please complete our site survey to gain access to the GlycoCheck Training Portal.

[Enroll for free](#)



GlycoCheck

microcirculation of ischemically injured kidneys from donors after cardiac death and living donor kidneys with minimal ischemia during transplant surgery. At 5 minutes after perfusion, the endothelial glycocalyx of donors-after-cardiac-death kidneys was significantly more degraded than that of the living donor kidney, suggesting that renal ischemia and reperfusion are associated with reduced capillary blood flow and loss of glycocalyx integrity."

Regarding Endocalyx Pro, the authors wrote "A potentially promising therapeutic approach is represented by Endocalyx Pro™, a combination of natural products each endowed with individual properties to accelerate restoration and prevent excessive degradation of glycocalyx. It contains brown seaweed extract called Laminaria japonica, rich in fucoidan sulfate – a hybrid of HS and CS. The fucoidan repairs the glycocalyx and prevents its breakdown by inhibiting heparanase activity. Another component is a high molecular weight hyaluronan. It is supplemented with glucosamine sulfate, providing the building blocks for glycocalyx synthesis. Further components include a proprietary blend of polyphenol and flavonoids with added superoxide dismutase and catalase (both from bitter melon concentrate)." Additional studies are ongoing about Endocalyx Pro and can be reviewed at Microvascular.com.

About BioRegenx

BioRegenx, Inc., (BioRegenx.com) a holding company, is the parent company of three wholly owned subsidiaries, Microvascular Health Solutions, LLC, My Body Rx, LLC, and NuLife Sciences, Inc. BioRegenx and its subsidiaries combine the patented intellectual property of the breakthrough GlycoCheck medical testing device, the patented nutraceutical Endocalyx Pro, additional synergistic dietary supplement products sold under the My Body Rx brand, and a customer base of medical professionals and brand partners throughout North America.

Safe Harbor

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements regarding potential sales, the success of the company's business, as well as statements that include the word believe or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of BioRegenx, Inc. to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and BioRegenx, Inc. assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customers to pay for ordered products, and political and economic risks inherent in international trade.

William Resides
BioRegenx
+1 800-398-9842

[email us here](#)

Visit us on social media:

[Facebook](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/584993435>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.